Dr. Brian Loggie, M.D. - Surgical Oncology, Colorectal Surgery

Brian Loggie, M.D.

Surgical Oncology
Colorectal Surgery

 Brian Loggie M.D.
Certification: Diplomate of the American Board of Surgery, 1990
Certificate of Training in Surgical Oncology - University of Illinois School of Medicine, Department of Surgery, Chicago, Illinois,
Re-certification, American Board of Surgery, General Surgery 2011
Medical School: McGill University
Residency: Montreal General Hospital, Montreal, Canada
Fellowship: University of Illinois at Chicago
Clinic Website: Abdominal Cancer Surgery

CHI Health Clinic

Surgical Oncology (Creighton, Suite 2803)

601 North 30th Street
Suite 2803
Omaha, NE 68131

Phone: 402-717-0090
Fax: 402-717-6068



Hospital Affiliation:

Brian W. Loggie, MD, CM, FRCSC, FACS grew up in Montreal, Canada and earned a Bachelor of Science degree from Montreal’s Loyal College. He received his Medical Degree from McGill University in 1979. From 1979-86, Dr. Loggie completed an internship and surgical residency at the Department of Surgery, Montreal General Hospital, Montreal, Canada . Concurrently with his residency, he completed graduate studies in the Department of Experimental Surgery, McGill University, Montreal, Canada, 1982-86.

Specialty Training
  • Clinical and Research Fellowship in Surgical Oncology, Division of Surgical Oncology, Department of Surgery, University of Illinois at Chicago, Chicago, Illinois, 1986-88
  • Specialist Certificate in General Surgery, Royal College of Physicians and Surgeons of Canada, 1986
  • Diplomate of the American Board of Surgery,1990
  • Certificate of Training in Surgical Oncology issued from University of Illinois School of Medicine, Department of Surgery, Chicago, Illinois, 1998
  • Re-certification, American Board of Surgery, General Surgery 2011.

Faculty Positions

Dr. Loggie has held faculty positions at University of Illinois at Chicago, Chicago, IL, 1986-88, Bowman Gray School of Medicine, Winston-Salem, NC, 1988-2000, University of Texas Southwestern Medical Center, Dallas, TX 2000-2002 and Creighton University School of Medicine, Omaha, NE, 2002-present. At Creighton University, Dr. Loggie serves as a Professor of Surgery and Chief in the Division of Surgical Oncology and Director of the Cancer Center at Creighton University Medical Center. In 2007, he was named holder of The Dr. Harold J. Bonnstetter Endowed Chair in Preventive Medicine at Creighton University School of Medicine.

Dr. Loggie's expertise is in surgical oncology and the management and treatment of rare cancers, including: peritoneal mesothelioma, cutaneous malignant melanoma, peritoneal carcinomatosis and malignant ascites, abdominopelvic and retroperitoneal sarcomas, pseudomyxoma peritonei, and management of complex primary or recurrent solid tumors. He also has an interest in peritoneal neoplastic disease, appendix neoplasms, gastrointestinal cancers, and ovarian cancer. His research interests also include Cox 2 mucinous cancers, estrogen receptor regulation and clinical trials for mesothelioma.

Before coming to the Creighton University School of Medicine, Dr. Loggie worked at Wake Forest University Baptist Medical Center in Winston-Salem, North Carolina, where he pioneered the use of heated chemotherapy and cytoreductive surgery for the treatment of peritoneal cancer. His research has led him to support the new and existing mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor as predictors of the optimal resectability in Mesothelioma.

Organizations/Societies

Fellow, Royal College of Surgeons of Canada; Fellow, Society of Surgical Oncology; Fellow, American College of Surgeons; Fellow, Southeastern Surgical Congress; Member, Canadian Association of General Surgeons; Member, North Carolina Medical Society; Member, Forsyth-Stokes-Davie County Medical Society; Member, Association for Academic Surgery; Member, American Medical Association; Member, Bowman Gray Surgical Society; Member New York Academy of Sciences; Member, North Carolina Chapter, American College of Surgeons; Member, Cancer and Leukemia Group B(CALGB); Member, Southern Association for Oncology; Fellow, American College of Surgeons; Member, United States Chapter of the Societe Internationale de Chiurgie; Member, American Society of Clinical Oncology (ASCO); Member, International Society for Regional Cancer Therapy; Member, North Carolina Surgical Association; Director, Mesothelioma Applied Research Foundation (MARF)

Honors

Selected by peers for inclusion in The Best Doctors in America, 2001-present. Accepted the 2010 Magis Award from Creighton University, Omaha, Nebraska on behalf and as a leader of, a Creighton-led health team that treated victims of the Haiti earthquake. Selected by peers for inclusion Castle Connoly's America's Top Doctors 2011.

Selected Publications/Abstracts

Shen P, Levine EA, Hall J, Case D, Russell G, Fleming RA, McQuellon RP, Geisinger KR, Loggie BW. Factors predicting survival following intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Archives of Surgery, 2003, 138: 26-33. archsurg.ama-assn.org/issues/v138n1/rfull/soa2119.html

McQuellon RP, Loggie BW, Lehman AB, Russell GB, Fleming RA, Shen P, Levine EA. Long term survivorship and quality of life following intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Annals of Surgical Oncology, 2003; in press.

Loggie BW, Wu Y, Saboorian MH, et al. Cox-2 and thymidylase synthase correlate with proliferative rates of mucinous tumors with diffuse peritoneal dissemination. ASCO, 2002, Abstract No: 1798. www.asco.org

Loggie BW, Fleming RA, McQuellon RP, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surg 2001;67:999-1003.

Loggie BW. Malignant peritoneal mesothelioma. Current Treatment Options in Oncology 2001:2:395-9.

Jackson SL, Fleming RA, Loggie BW, Geisinger KR. Gelatinous ascites: A cytohistologic study of pseudomyxoma peritonei in 67 patients. Mod Pathol 2001;14:664-71. modpath.uscapjournals.org/cgi/content/full/14/7/664

McQuellon RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD. Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Onc 2001;27:65-73.

Fleming RA, Loggie BW, Russell GB, Rice MA: Systemic exposure of mitomycin C during intraperitoneal hyperthermic administration is correlated with hematologic toxicity and survival in patients with peritoneal carcinomatosis. Proc Am Assoc Cancer Res 1998;39:599.

Chen MY, Chiles C, Loggie BW, et al. Thoracic complications in patients undergoing intraperitoneal heated chemotherapy with mitomycin following cytoreductive surgery. J Surg Onc 1997;66:19-23. Loggie BW, Fleming RA, Hosseinian AA. Peritoneal carcinomatosis with urachal signet-cell adenocarcinoma: A case report. Urology 1997;50:446-8.
www.urologyonline.it/bag/carcper.txt

Loggie BW, Perini M, Fleming RA, et al. Treatment and prevention of malignant ascites associated with disseminated intraperitoneal malignancies by aggressive combined-modality therapy. Am Surg 1997;63:137-43
www.sesc.org/surgeon/0297abs.htm

Loggie BW, Fleming RA, Geisinger KR. Cytologic assessment before and after intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Acta Cytol 1996;40:1154-8. www.acta-cytol.com

Dr. Loggie personal interests include piloting aircraft and taekwondo.